Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
PMV Pharmaceuticals (PMVP) Stock Price & Analysis
81 Followers
PMVP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.18 - $9.72
Previous Close$1.56
Volume166.46K
Average Volume (3M)500.60K
Market Cap
$80.25M
Enterprise Value-$104.67M
Total Cash (Recent Filing)$197.94M
Total Debt (Recent Filing)$13.02M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 08, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding51,443,488
10 Day Avg. Volume421,879
30 Day Avg. Volume500,604
Standard Deviation0.25
R-Squared0.10
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.37
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda2.88
Forecast
1Y Price Target
$5.00Price Target Upside220.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
PMV Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical SuccessMeaningful response rates were seen in ovarian, breast, small-cell lung, and endometrial cancer types.
Financial StrengthPMV ended 1Q24 with $213.1M in cash, which in our view should fund operations to end-2026.
Strategic CollaborationCollaboration agreement inked with Foundation Medicine for companion diagnostic.
Bears Say
Clinical TrialsRisks include negative PC14586 clinical data and delays in moving candidates into advanced trials.
Financial PerformanceA net loss of $0.30 per share was recorded in 1Q24.
Treatment DeploymentA low probability of PC14586 monotherapy deployment in a tumor-agnostic fashion.
---
Ownership Overview
53.68% Insiders
20.12% Mutual Funds
5.40% Other Institutional Investors
20.80% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PMVP FAQ
What was PMV Pharmaceuticals’s price range in the past 12 months?
PMV Pharmaceuticals lowest stock price was $1.18 and its highest was $9.72 in the past 12 months.
What is PMV Pharmaceuticals’s market cap?
Currently, no data Available
When is PMV Pharmaceuticals’s upcoming earnings report date?
PMV Pharmaceuticals’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were PMV Pharmaceuticals’s earnings last quarter?
PMV Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.06.
Is PMV Pharmaceuticals overvalued?
According to Wall Street analysts PMV Pharmaceuticals’s price is currently Undervalued.
Does PMV Pharmaceuticals pay dividends?
PMV Pharmaceuticals does not currently pay dividends.
What is PMV Pharmaceuticals’s EPS estimate?
PMV Pharmaceuticals’s EPS estimate is -$0.35.
How many shares outstanding does PMV Pharmaceuticals have?
PMV Pharmaceuticals has 51,443,490 shares outstanding.
What happened to PMV Pharmaceuticals’s price movement after its last earnings report?
PMV Pharmaceuticals reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went down -2.778%.
Which hedge fund is a major shareholder of PMV Pharmaceuticals?
Among the largest hedge funds holding PMV Pharmaceuticals’s share is Baker Bros Advisors LP. It holds PMV Pharmaceuticals’s shares valued at 547K.
---
PMV Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (220.51% Upside)
$5.00 (220.51% Upside)
Blogger Sentiment
Bullish
PMVP Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.12%
12-Months-Change
Fundamentals
Return on Equity
-29.40%
Trailing 12-Months
Asset Growth
-6.73%
Trailing 12-Months
Company Description
PMV Pharmaceuticals
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
---
PMVP Stock 12 Month Forecast
Average Price Target
$5.00
▲(220.51% Upside)
Technical Analysis
Best Analysts Covering PMVP
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-32.70%
assigned a buy rating 5 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -32.70% per trade.
---